netFormulary NHS
Bedfordshire and Luton Joint Formulary
Bedford Hospital NHS Trust
Bedfordshire CCG
Luton & Dunstable University Hospital NHS Foundation Trust
Luton CCG
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing

 Details...
06.06.02  Expand sub section  Bisphosphonates and other drugs affecting bone metabolism
06.06.02  Expand sub section  Bisphosphonates
Alendronic Acid
View adult BNF View SPC online View childrens BNF
First Choice
Green

10mg & 70mg Tablets
1st Choice for osteoporosis

Not licensed for use in men

 
Risedronate
View adult BNF View SPC online View childrens BNF
Second Choice
Green
2nd Choice for osteoporosis
2nd line treatment when intolerant to alendronate.
5mg & 35mg Tablets 
   
Disodium Pamidronate
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
15mg, 30mg, 60mg, 90mg Injection
 
Link  MHRA Drug Safety Update (July 2015) - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
   
Ibandronic Acid 50mg
(Tablets)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Amber

Restricted - initiation by Consultant Oncologists with continuation by GPs for adjuvant treatment in early breast cancer.

 
   
Sodium Clodronate
View adult BNF View SPC online View childrens BNF
Formulary
Amber

400mg, 800mg Tablets

 
   
Zoledronic Acid 4mg
(Injection for infusion)
View adult BNF View SPC online View childrens BNF
Formulary
Red

L&D: For licensed indications in cancer patients.

Note: Bedford Hospital only currently use 4mg doses for all indications due to cost of 5mg preparation (November 2018)

 
Link  Drug Safety Update: Osteonecrosis of the jaw - further measures to minimise risk
   
Zoledronic Acid 5mg
(Intravenous infusion)
View adult BNF View SPC online View childrens BNF
Formulary
Red

1. For osteoporosis treatment in line with NICE guidelines

2. Restricted -  Consultant Oncologists for adjuvant treatment in early breast cancer.

Note: Bedford Hospital only currently use 4mg doses for all indications due to cost of 5mg preparation (November 2018)

Note: L&D use 2x4mg vials for a 5mg dose due to cost of the 5mg preparation (approved by DTC).

 
Link  Drug Safety Update: Osteonecrosis of the jaw - further measures to minimise risk
   
06.06.02  Expand sub section  Denosumab
06.06.02  Expand sub section  Strontium renelate
 ....
 Non Formulary Items
Alendronic Acid with colecalciferol  (Fosavance®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ibandronic Acid injection  (Bonviva®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ibandronic acid IV infusion  (Bondronat®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Tiludronic Acid  (Skelid®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment  

Amber

Amber medicines are considered suitable for GP prescribing following specialist initiation.  

Green

These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations   

Amber SCG

Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.   

Black

A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. Do not prescribe.   

netFormulary